Business
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a pote
About this update from Zentalis Pharmaceuticals, Inc.
[{"type":"image","alt":"ZENTALIS PHARMACEUTICALS","displaySize":"","headline":null,"caption":"ZENTALIS PHARMACEUTICALS","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/8a2329194a3b92e9d92b6dddf1b01631"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nQzP_GawPdWO8YMImzkdkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8a2329194a3b92e9d92b6dddf1b01631","width":300,"height":87}},"lazy":false},{"type":"text","content":"First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC","length":100,"tagName":"p"},{"type":"text","content":" Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback","length":139,"tagName":"p"},{"type":"text","content":"$332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027","length":106,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, announced financial results for the first quarter 2025 and highlighted recent operational progress.","length":363,"tagName":"p"},{"type":"text","content":""We continued advancement of azenosertib and made solid progress against our strategic goals in the first quarter. The initiation of DENALI Part 2 moves us into a new chapter as a late-stage development company focusing on a significant patient population in platinum-resistant ovarian cancer with limited choices," said Julie Eastland, Chief Executive Officer of Zentalis. “Our team remains focused on the enrollment and execution of DENALI. Zentalis is financially and organizationally well-positioned to continue advancing azenosertib as a potential treatment option for PROC patients.”","length":599,"tagName":"p"},{"type":"text","content":"Program Highlights","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First patient dosed in Part 2 of the Phase 2 DENALI clinical trial. ","length":68,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"t...